Student Research Committee, Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Iran J Kidney Dis. 2020 Mar;14(2):126-132.
CKD is one of the most prevalent entities associated with high morbidity and mortality. Most of the patients with renal diseases, particularly patients undergoing dialysis, suffer from cardiovascular disease and it is necessary to employ appropriate strategies to prevent and manage this complication. The aim of this study was to evaluate the anti-inflammatory effects of omega-3 in patients undergoing CAPD.
Nineteen CAPD patients with certain inclusion and exclusion criteria enrolled in this study. Omega-3 capsules with a dose of 1 g/d up to three months, were administrated. Some inflammatory markers such as ESR, CRP, HS-CRP, IL-6, MDA, and homocysteine were measured in three phases. In addition, lipid profile including triglyceride, cholesterol, LDL, and HDL were measured.
Results of this study showed that CRP, HS-CRP, and homocysteine levels increased insignificantly (P > .05) whereas, MDA level was increased significantly (P < .05). ESR and IL-6 levels both decreased but did not show any statistically significance (P > .05). Results of lipid profile also suggested that none of the lipid levels changed significantly (P > .05).
It is necessary to design large trials in order to understand clear effects of omega-3 on inflammatory markers in PD patients. In addition, the results of this current pilot study should be interpreted with caution.
慢性肾脏病 (CKD) 是与高发病率和死亡率最相关的实体之一。大多数肾脏疾病患者，特别是接受透析的患者，都患有心血管疾病，因此有必要采用适当的策略来预防和管理这种并发症。本研究旨在评估ω-3 对接受 CAPD 的患者的抗炎作用。
19 名符合特定纳入和排除标准的 CAPD 患者参与了这项研究。给予 ω-3 胶囊，剂量为 1 克/天，持续三个月。在三个阶段测量了一些炎症标志物，如 ESR、CRP、hs-CRP、IL-6、MDA 和同型半胱氨酸。此外，还测量了血脂谱，包括甘油三酯、胆固醇、LDL 和 HDL。
本研究结果表明，CRP、hs-CRP 和同型半胱氨酸水平升高不显著（P>.05），而 MDA 水平升高显著（P<.05）。ESR 和 IL-6 水平均降低，但无统计学意义（P>.05）。血脂谱的结果也表明，没有任何血脂水平发生显著变化（P>.05）。
有必要设计更大的试验，以了解 ω-3 对 PD 患者炎症标志物的明确作用。此外，应谨慎解释本当前初步研究的结果。
